European Neuropsychopharmacology最新文献

{"title":"Association between genetic risk of attention deficit hyperactivity disorder and trajectories of daily gaming time in children","authors":"Nagahide Takahashi , Akemi Okumura , Tomoko Nishimura , Taeko Harada , Toshiki Iwabuchi , Md Shafiur Rahman , Kenji J. Tsuchiya","doi":"10.1016/j.euroneuro.2024.11.012","DOIUrl":"10.1016/j.euroneuro.2024.11.012","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 54-55"},"PeriodicalIF":6.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of mortality and complications in patients with severe mental illness and co-occurring diabetes mellitus: A systematic review and meta-analysis","authors":"Matthew Tsz Ho Ho ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Will Chi Yuen Chiu ,&nbsp;Lucy Lo Wah Tsang ,&nbsp;Kenneth Shut Wah Chan ,&nbsp;Mimi Mei Cheung Wong ,&nbsp;Ho Hon Wong ,&nbsp;Pui Fai Pang ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.11.002","DOIUrl":"10.1016/j.euroneuro.2024.11.002","url":null,"abstract":"<div><div>People with severe-mental-illness (SMI), often defined as “schizophrenia-spectrum disorders and bipolar disorder”, have increased premature mortality and elevated prevalence of diabetes compared with general population. Evidence indicated that one-third of their premature death was from cardiovascular diseases (CVD), with risk conferred by diabetes. Although earlier studies have examined SMI-associated diabetes-related outcomes, findings were inconsistent and not systematically evaluated. We systematically reviewed and quantitatively synthesized diabetes-related outcomes in patients with SMI (schizophrenia-spectrum disorders and bipolar disorder) by searching Embase, MEDLINE, PsycInfo, and Web-of-Science from inception to 31-March-2024, and included studies examining mortality and complication outcomes in SMI patients with co-occurring diabetes relative to patients with diabetes-only. Results were synthesized by random-effects models, with stratified-analyses by study-level characteristics. The study was registered with PROSPERO (CRD42023448490). Twenty-one studies involving 161,156 SMI patients with co-occurring diabetes were identified from ten regions. Regarding mortality risk, SMI-diabetes group exhibited increased risks of all-cause mortality (RR=1.77[95 % CI: 1.46–2.14]) and CVD-specific mortality (1.88[1.73–2.04]) relative to diabetes-only group. All-cause mortality risk was present in distinct regions and has persisted over time. Regarding complication risk, SMI-diabetes group showed higher risk of any complications (1.23[1.06–1.43]) than comparison, with stratified-analyses showing higher risk of metabolic-complications (1.84[1.58–2.15]), and lower likelihood of peripheral-vascular complications (0.91[0.84–0.99]), neuropathy (0.85[0.78–0.93]), and retinopathy (0.70[0.60–0.82]), albeit comparable cardiovascular-complications (1.04[0.89–1.22]), cerebrovascular-complications (1.07[0.86–1.33]), and nephropathy (0.92[0.72–1.17]). High heterogeneity was noted and could not be fully-explained by subgroup-analyses. Implementation of targeted interventions is needed to rectify their diabetes-related outcomes and mortality gap.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 25-36"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial DNA copy number is significantly increased in bipolar disorder patients and is correlated with long-term lithium treatment","authors":"Anna Meloni ,&nbsp;Pasquale Paribello ,&nbsp;Marco Pinna ,&nbsp;Martina Contu ,&nbsp;Raffaella Ardau ,&nbsp;Caterina Chillotti ,&nbsp;Donatella Congiu ,&nbsp;Massimo Gennerelli ,&nbsp;Alessandra Minelli ,&nbsp;Lisa Buson ,&nbsp;Giovanni Severino ,&nbsp;Claudia Pisanu ,&nbsp;Mirko Manchia ,&nbsp;Alessio Squassina","doi":"10.1016/j.euroneuro.2024.10.012","DOIUrl":"10.1016/j.euroneuro.2024.10.012","url":null,"abstract":"<div><div>Mitochondrial dysfunctions have been reported in bipolar disorder (BD), but their role in the etiopathogenesis of BD as well as their implications in modulating response to pharmacological treatments with psychotropic medications have been scarcely explored. Mitochondrial DNA copy number (mtDNA-cn) has been linked to mitochondria functioning, and, despite some degree of inconsistence, previous findings showed that BD patients present significant differences in mtDNA-cn compared to healthy controls. Here we measured mtDNA-cn in a sample of 89 patients with BD and 78 healthy controls (HC). Patients in the BD sample were treated either with lithium (<em>n</em> = 47) and characterized as responders (<em>n</em> = 22) or non-responders (<em>n</em> = 25), or with other mood stabilizers (<em>n</em> = 42). BD patients had larger mtDNA-cn compared to HC (adjusted model: F₂=9.832; <em>p</em> = 0.000095; contribution of diagnosis F₁= 10.798; <em>p</em> = 0.001). When the BD sample was stratified for treatment exposure, mtDNA-cn was lower in patients treated with lithium compared to those treated with other mood stabilizers (adjusted model: F₄=23.770, <em>p</em> = 7.0929E-13; contribution of treatment: F₁=54.300, <em>p</em> = 1.55E-10). Moreover mtDNA-cn was higher in patients treated with other mood stabilizers compared to controls and Li-treated BD patients (F₃=28.125, <em>p</em> = 1.36E-14; contribution of groups F₂=36.156, <em>p</em> = 1.25E-13). Finally, there was no difference in mtDNA-cn levels in lithium responders compared to non-responders and neither between the two diagnostic groups (BD type 1 and 2). Our findings suggest that BD may be associated with mitochondrial dysfunctions, and that exposure to lithium but not to other mood stabilizers may restore these abnormalities, though this does not appear correlated with the clinical efficacy of lithium.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 37-44"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis use and psychosis: evidence and new clinical features of a new epidemic","authors":"Giovanni Martinotti ,&nbsp;Marta Di Forti","doi":"10.1016/j.euroneuro.2024.11.007","DOIUrl":"10.1016/j.euroneuro.2024.11.007","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 45-46"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing differential diagnostics and identifying transdiagnostic treatment targets using virtual reality","authors":"Hanne Lie Kjærstad ,&nbsp;Andreas Elleby Jespersen ,&nbsp;Johanne Lilmose Bech ,&nbsp;Sofie Weidemann ,&nbsp;Anne Juul Bjertrup ,&nbsp;Emilie Hestbæk Jacobsen ,&nbsp;Sebastian Simonsen ,&nbsp;Louise Birkedal Glenthøj ,&nbsp;Merete Nordentoft ,&nbsp;Kristian Reveles ,&nbsp;Tine Wøbbe ,&nbsp;Mads Lopes ,&nbsp;Daniel Lyngholm ,&nbsp;Kamilla Woznica Miskowiak","doi":"10.1016/j.euroneuro.2024.11.006","DOIUrl":"10.1016/j.euroneuro.2024.11.006","url":null,"abstract":"<div><div>Accurate diagnosis in psychiatry remains a significant challenge, often delaying appropriate treatment and resulting in poorer clinical outcomes. Identifying precise biomarkers for differential diagnosis is therefore crucial. This study aimed to identify distinct behavioral and psychophysiological markers of emotional reactivity in virtual reality (VR) settings among individuals with bipolar disorder (BD), borderline personality disorder (BPD), schizophrenia spectrum disorders (SSD), and healthy controls (HC). Participants (BD: <em>n</em> = 32, BPD: <em>n</em> = 21, SSD: <em>n</em> = 17, HC: <em>n</em> = 30) aged 19–60 were exposed to six immersive 360-degree social VR scenarios, ranging from neutral to highly emotional contexts (e.g., an elevator ride, a crying baby). Emotional responses were self-rated on a 1–5 scale, while galvanic skin response (GSR) was continuously recorded. Scenarios assessed feelings of unpleasantness, pleasantness, being observed, and the urge to comfort. Across diagnoses, individuals with mental health conditions reported more negative emotional responses (greater unpleasantness) across both neutral and negative scenarios (<em>p</em>s ≤ 0.02) despite similar GSR levels to HC. Specifically, in the elevator scenario, BPD and SSD experienced greater unpleasantness and feelings of being observed, coupled with stronger GSRs compared to BD (<em>p</em>s ≤ 0.03). SSD reported higher unpleasantness in the canteen scenario, less pleasantness in the happy baby scenario, and overall higher GSR than BD (<em>p</em>s ≤ 0.049). Negative emotional reactivity was consistent across BD, BPD, and SSD, with heightened emotional and physiological responses distinguishing SSD and BPD from BD in specific VR contexts. VR-based assessments of emotional and physiological markers show promise for improving differential diagnosis and identifying transdiagnostic treatment targets.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 1-9"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Genetic variation in schizophrenia: Are the most obvious ‘druggable pathways’ hiding in plain sight?","authors":"Mark Ainsley Colijn","doi":"10.1016/j.euroneuro.2024.11.010","DOIUrl":"10.1016/j.euroneuro.2024.11.010","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 52-53"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valproate's impact on future generations — A call for stricter guidelines for maternal and paternal use","authors":"Meritxell González-Campos ,&nbsp;Helena Andreu ,&nbsp;Oscar De Juan ,&nbsp;Luis Olivier ,&nbsp;Gerard Anmella","doi":"10.1016/j.euroneuro.2024.11.005","DOIUrl":"10.1016/j.euroneuro.2024.11.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 50-51"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical sleep staging for insomnia disorder","authors":"Christophe Gauld ,&nbsp;Tessa Blanken","doi":"10.1016/j.euroneuro.2024.11.009","DOIUrl":"10.1016/j.euroneuro.2024.11.009","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 47-49"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Lung function decline in people with serious mental illness: A call to action” [European Neuropsychopharmacology (2024) 41-46/ ENP-24-342]","authors":"Cristina Ruiz-Rull ,&nbsp;María José Jaén-Moreno ,&nbsp;Gloria Isabel del Pozo ,&nbsp;Cristina Camacho-Rodríguez ,&nbsp;Marta Rodríguez-López ,&nbsp;Fernando Rico-Villademoros ,&nbsp;José Luis Otero-Ferrer ,&nbsp;Nuria Feu ,&nbsp;Micaela Reyes-López ,&nbsp;Rosa M. Fiestas ,&nbsp;David Laguna-Muñoz ,&nbsp;Ana Jiménez-Peinado ,&nbsp;David Mannino ,&nbsp;Eduard Vieta ,&nbsp;Fernando Sarramea","doi":"10.1016/j.euroneuro.2024.11.004","DOIUrl":"10.1016/j.euroneuro.2024.11.004","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Page 79"},"PeriodicalIF":6.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The need for specific mental health interventions for the prevention of suicide in postpandemic times","authors":"Alejandro de la Torre-Luque ,&nbsp;Jose Luis Ayuso-Mateos","doi":"10.1016/j.euroneuro.2024.10.007","DOIUrl":"10.1016/j.euroneuro.2024.10.007","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 77-78"},"PeriodicalIF":6.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}